Molecular Characteristics of Extended-Spectrum β-Lactamases in Clinical Isolates from Escherichia coli at a Japanese Tertiary Hospital

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yano, Hisakazu ^a   Uemura, Mina ^a   Endo, Shiro ^a   Kanamori, Hajime ^a   Inomata, Shinya ^a   Kakuta, Risako ^a   Ichimura, Sadahiro ^b   Ogawa, Miho ^b   Shimojima, Masahiro ^b   Ishibashi, Noriomi ^a   Aoyagi, Tetsuji ^a   Hatta, Masumitsu ^a   Gu, Yoshiaki ^a   Yamada, Mitsuhiro ^a   Tokuda, Koichi ^a   Kunishima, Hiroyuki ^a   Kitagawa, Miho ^a   Hirakata, Yoichi ^a   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kawagoe shi   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 15; BETA LACTAMASE CTX M 27; BETA LACTAMASE OXA 1; BETA LACTAMASE SHV; BETA LACTAMASE SHV 12; BETA LACTAMASE TEM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

AAC(6') IB CR GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLACTX M GENE; BLAOXA 1 LIKE GENE; BLASHV GENE; BLATEM GENE; CONTROLLED STUDY; CTX M 15 GENE; ESCHERICHIA COLI; GENE SEQUENCE; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR GENETICS; NONHUMAN; PLASMID; QEPA GENE; QNRB GENE; QNRS GENE; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

BETA-LACTAMASES; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; JAPAN; MICROBIAL SENSITIVITY TESTS; TERTIARY CARE CENTERS;

EID: 84877733378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064359     Document Type: Article

References (27)

1. Cantón R, Coque TM, (2006) The CTX-M β-lactamase pandemic. Current Opinion in Microbiology 9: 466-75.
2. Pitout JDD, Laupland KB, (2008) Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8: 159-166.
3. Bonnet R, (2004) Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48: 1-14.
4. Heffernana HM, Woodhousea RE, Popea CE, Blackmore TK, (2009) Prevalence and types of extended-spectrum β-lactamases among urinary Escherichia coli and Klebsiella spp. in New Zealand. Int J Antimicrob Agents 34: 544-549.
5. Peirano G, Pitout JDD, (2010) Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35: 316-321.
6. Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, et al. (2007) Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 51: 1281-1286.
7. Pitout JDD, Hanson ND, Church DL, Laupland KB, (2004) Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 38: 1736-1741.
8. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, et al. (2009) Change in the prevalence of extended-spectrum β-actamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 63: 72-79.
9. Martinez-Martinez L, Pascual A, Jacoby GA, (1998) Quinolone resistance from a transferable plasmid. Lancet 351: 797-799.
10. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, et al. (2001) Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33: 1288-1294.
11. Robicsek A, Jacoby GA, Hooper DC, (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6: 629-640.
12. Ode T, Saito R, Kumita W, Sato K, Okugawa S, et al. (20099 Analysis of plasmid-mediated multidrug resistance in Escherichia coli and Klebsiella oxytoca isolates from clinical specimens in Japan. Int J Antimicrob Agents 34: 347-350.
13. Clinical and Laboratory Standards Institute. (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
14. Clinical and Laboratory Standards Institute. (2009) Performance standards for antimicrobial susceptibility testing; Nineteenth informational supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
15. Kanamori H, Yano H, Hirakata Y, Endo S, Arai K, et al. (2011) High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: Dissemination of CTX-M-2. J Antimicrob Chemother 66: 2255-2262.
16. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, et al. (2006) Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 58: 665-668.
17. Muzaheed, Doi Y, Adams-Haduch JM, Endimiani A, Sidjabat HE, et al. (2008) High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. J Antimicrob Chemother 61: 1393-1394.
18. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, et al. (2010) Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-β-lactamase-producing Escherichia coli among companion animals. J Antimicrob Chemother 65: 651-660.
19. Jørgensen RL, Nielsen JB, Friis-Møller A, Fjeldsøe-Nielsen H, Schønning K, (2010) Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J Antimicrob Chemother 65: 460-464.
20. Ministry of Health, Labour, and Welfare. (2011) Ethical guidelines of epidemiology study [in Japanese].
21. Kuroda H, Yano H, Hirakata Y, Arai K, Endo S, et al. (2012) Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Japan: Emergence of CTX-M-15-producing E. coli ST131. Diagn Microbiol Infect Dis 74: 201-203.
22. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A, (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clinical Microbiology Reviews 22: 664-689.
23. Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, et al. (2003) Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 52: 29-35.
24. Ender PT, Gajanana D, Johnston B, Clabots C, Tamarkin FJ, et al. (2009) Transmission of extended-spectrum β-lactamase-producing Escherichia coli (sequence type ST131) between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 47: 3780-3782.
25. Johnson JR, Anderson JT, Clabots C, Johnston B, Cooperstock M, (2010) Within-household sharing of a fluoroquinolone-resistant Escherichia coli sequence type ST131 strain causing pediatric osteoarticular infection. Pediatr Infect Dis J 29: 474-475.
26. Owens RC Jr, Johnson JR, Stogsdill P, Yarmus L, Lolans K, et al. (2011) Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death. J Clin Microbiol 49: 3406-3408.
27. Vigil KJ, Johnson JR, Johnston BD, Kontoyiannis DP, Mulanovich VE, et al. (2010) Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 50: 374-380.